Nitrosamines After the Initial Assessment: When Does a Change Trigger Reassessment and How Should Impact Be Evaluated

A nitrosamine risk assessment is often straightforward when the process, materials, suppliers, and product remain unchanged. The truly difficult decisions begin during lifecycle management when something changes. A new supplier is introduced. A reagent is replaced. A manufacturing site is transferred. A formulation is modified. An unexpected analytical result is reported. Teams must determine whether the existing risk assessment remains scientifically defensible or whether a formal reassessment, confirmatory testing, or additional control strategies are required.

This technical webinar focuses entirely on the critical decisions that follow post-approval change. Participants will learn how experienced pharmaceutical organizations evaluate reassessment triggers, determine the significance of supplier, process, formulation, and manufacturing modifications, and decide when physical testing is strictly warranted versus when a scientific rationale suffices. The session will deeply examine the application of ICH M7 purge assessments, the classification of Nitrosamine Drug Substance Related Impurities (NDSRIs) using CPCA principles, the justification of testing strategies, and the development of agile control approaches that remain fully compliant as products, processes, and international regulatory expectations continue to evolve.

| WHY YOU SHOULD ATTEND

Few life science organizations still struggle with the initial phase of identifying potential nitrosamine risks. The greater, ongoing operational challenge is determining exactly what to do after a change occurs. The same high-stakes question repeatedly surfaces across Change Control reviews, technical assessments, supplier evaluations, deviation investigations, Annual Product Reviews (APR) / Product Quality Reviews (PQR), and global regulatory submissions: Does this change require a nitrosamine reassessment?

The answer is rarely obvious or binary. Some lifecycle changes necessitate immediate confirmatory testing, revised specifications, or a comprehensive overhaul of the regulatory dossier. Others require only a highly robust, documented scientific rationale. This webinar demystifies how those decisions are made. Participants will review the exact technical factors used to evaluate change impact, understand when a purge-based justification can legally bypass laboratory analysis, and assess whether existing control strategies remain resilient. The session also directly addresses the latest NDSRI categorization matrix, specification limit decisions, evolving Acceptable Intake (AI) calculations, and the practical, harmonized application of current USFDA, EMA, Health Canada, ANVISA, and TGA expectations.

| LEARNING OBJECTIVES

By the end of this intensive 2-hour session, participants will be able to:

• Determine with scientific precision when a post-approval change triggers a mandatory, documented nitrosamine reassessment versus when the existing Step 1 assessment remains regulatory-defensible.
• Evaluate the complex impact of supplier shifts, raw material variations, excipient nitrites/amines, process modifications, formulation adjustments, and manufacturing site transfers on overall nitrosamine risk profiles.
• Assess whether laboratory confirmatory testing is legally necessary or whether a robust, data-driven scientific justification can independently support the change control.
• Apply ICH M7 semi-quantitative purge scoring concepts to support change impact evaluations and justify the absence of routine downstream testing.
• Distinguish minor lifecycle changes from material changes that fundamentally alter the thermodynamic or kinetic potential for nitrosamine formation.
• Evaluate complex NDSRIs using current CPCA-based structural feature scoring when compound-specific rodent carcinogenicity data is unavailable.
• Select and defend appropriate control strategies (e.g., Option 1–4 controls) based on process capability, process understanding, and available analytical limits of quantification (LOQ).
• Build audit-ready, highly defensible reassessment rationales capable of seamlessly passing global regulatory reviews, health authority inspections, and annual PQR audits.

| TECHNICAL CONTENT AND MODULE BREAKDOWN

Module 1: Determining When Nitrosamine Reassessment Should Be Initiated

• The Regulatory Paradigm Shift: Moving from the initial deadlined mandates (Step 1 Risk Evaluation) into active, continuous Quality Risk Management (QRM) under ICH Q9(R1) and lifecycle management under ICH Q12.
• Defining the "Trigger": Identifying the exact regulatory and technical boundaries where an existing risk assessment is rendered obsolete.
• Regulatory Expectations Compared: Cross-evaluating current mandates from the USFDA, EMA (Article 5(3)), Health Canada, ANVISA, and TGA regarding post-marketing surveillance and immediate notification obligations upon discovering new risk paths.
• The Chronological Reassessment Workflow: Establishing internal standard operating procedures (SOPs) that cleanly interface your Change Control management system with your Nitrosamine Core Team.

Module 2: Supplier Changes, Raw Material Changes, and Excipient Changes

• The Risk of the Unseen: How changing an Active Pharmaceutical Ingredient (API) or Key Starting Material (KSM) supplier introduces hidden risks via altered synthetic routes, recovery processes, or recycled solvents.
• Excipient-Driven Nitrosation: Evaluating the critical risk of micro-levels of inorganic nitrites ($NO_2^-$) in common excipients (e.g., microcrystalline cellulose, lactose, starch, povidone, crospovidone).
• The Amine Component: Assessing secondary or tertiary amines present as structural elements, degradation products, or processing aids within the excipient matrix.
• Supplier Qualification Strategy: Moving beyond the standard vendor Questionnaire — establishing proactive vendor-derived nitrite monitoring, mass balance calculations, and cross-contamination risk bounds for recovered materials.

Module 3: Process Changes, Synthetic Route Modifications, Reagents, Catalysts, and Solvents

• Altered Kinetics & Thermodynamics: How subtle modifications in reaction temperature, pH, hold times, and crystallization steps can dramatically favor or accelerate nitrosamine formation.
• Reagents and Catalysts: Evaluating the direct introduction of nitrosating agents (e.g., $NaNO_2$, alkyl nitrites) or secondary/tertiary amines used as bases or phase-transfer catalysts (e.g., TEA, DIPEA, TBA).
• The Solvent Dilemma: The severe risks associated with fresh vs. recovered/recycled solvents (e.g., DMF, DMAc, NMP) and the potential for cross-contamination in shared recovery infrastructure.
• Azide Mitigation Pitfalls: Analyzing how steps taken to destroy residual azides using nitrous acid can inadvertently drive massive nitrosamine spikes if secondary or tertiary amines are present in the same chemical environment.

Module 4: Formulation Changes, Manufacturing Transfers, and Other Product Lifecycle Changes

• Solid State vs. Liquid Phase Reactions: Evaluating how changing a formulation (e.g., switching from dry granulation to wet granulation) introduces moisture and local pH microenvironments that accelerate NDSRI formation during shelf life.
• Primary Packaging Risks: Assessing the migration of nitrocellulose printing inks from lamination foils or the leaching of vulcanizing agents and secondary amines from rubber stoppers and lidding materials.
• Manufacturing Site Transfers: Evaluating the impact of changes in equipment geometry, fluid bed dryer design, localized hotspots, and the risk of airborne or cleaning-validation-related cross-contamination in multi-product facilities.
• Unexpected Analytical Stability Results: How to manage and investigate a sudden "Out of Specification" (OOS) or "Out of Trend" (OOT) nitrosamine result during ongoing stability programs for a previously validated product.

Module 5: Evaluating Change Impact and Establishing Reassessment Requirements

• Risk Categorization Matrix: Constructing a highly effective, scannable technical framework to classify post-approval changes based on their chemical probability of driving nitrosation.
• Scientific Rationale Development: Drafting the critical technical bridge between Change Control initiation and regulatory dossier variation submissions.
• Impact of Acceptable Intake (AI) Shifts: How a newly published, lowered regulatory AI value for a specific nitrosamine automatically triggers a retroactive impact evaluation on existing, approved processes.

Module 6: Confirmatory Testing Versus Purge-Based Scientific Justification

• When Testing is Non-Negotiable: Definitive regulatory thresholds (USFDA/EMA) that mandate immediate analytical verification (e.g., high-risk factors combined with lack of historical batch data).
• ICH M7 Purge Factor Framework: Utilizing the semi-quantitative purge calculation tool to scientifically justify why laboratory testing is not required.
• The Scoring Logic: Applying structural, reactivity, solubility, and volatility purge parameters to demonstrate that the process possesses an inherent, validated purging capacity 
• Dossier Documentation: How to present a purge-based justification that successfully withstands aggressive scrutiny by EDQM or Health Canada reviewers without prompting formal deficiency letters.

Module 7: NDSRI Assessment and Application of CPCA Principles

• The NDSRI Challenge: Understanding why Nitrosamine Drug Substance Related Impurities represent the single most complex challenge in modern pharmaceutical lifecycle management.
• Carcinogenic Potency Categorization Approach (CPCA): A deep dive into the harmonized approach adopted by FDA, EMA, Health Canada, ANVISA, and TGA for predicting nitrosamine potency based on structural features.
• The Step-by-Step CPCA Scoring System:
  1. Count of Hydrogen Atoms on the alpha-carbons.
  2. Deactivating Features: Presence of electron-withdrawing groups, carboxylic acids, or steric hindrance that decreases nitrosation/activation potential.
  3. Activating Features: Rings, chains, or specific structural additions that amplify mutagenic risk.
  4. Final Potency Category Assignment: Categorizing the molecule into Potency Category 1, 2, 3, 4, or 5, and automatically determining its corresponding Acceptable Intake (AI) limit (ranging from 26 ng/day to 1500 ng/day).
• Surrogate Selection Criteria: Choosing highly accurate structural analogues when utilizing read-across approaches or enhanced Ames testing paradigms.

Module 8: Testing Strategies, Control Strategies, Mitigation Measures, and Ongoing Monitoring Expectations

• The Analytical Armory: Selecting and validating ultra-sensitive methods including LC-MS/MS and GC-MS/MS featuring specialized Limits of Quantification (LOQ) capable of tracking parts-per-billion (ppb) concentrations.
• ICH Q6A Control Options:
  • Option 1: Control testing in the finished product specification at or below the AI limit.
  • Option 2: Control testing in the API or intermediate specification at or below the AI limit.
  • Option 3: Control testing upstream with a validated, robust purge justification.
  • Option 4: Omission of routine testing based on clear process understanding and analytical results consistently staying below 10% of the AI limit.
• Formulation Mitigation Engineering: Implementing proactive formulation barriers, such as adding antioxidants (e.g., Ascorbic Acid, Alpha-Tocopherol) or amino acids (e.g., L-Lysine, L-Arginine) to physically inhibit the inline formation of NDSRIs during shelf life.
• Continuous Lifecycle Compliance: Integrating continuous monitoring expectations into your Annual Product Review (APR/PQR) to maintain absolute state-of-control compliance.

| WHO SHOULD ATTEND

This technical training is custom-engineered for senior technical professionals, managers, and directors operating across the global life sciences space, specifically within:

• Quality Assurance (QA) Departments – Professionals who authorize or reject Change Controls, deviations, and market release.
• Regulatory Affairs (RA) & Regulatory CMC Departments – Managers compiling variations, dossiers, and interacting with FDA, EMA, Health Canada, ANVISA, and TGA.
• Quality Control (QC) & Analytical Development Departments – Scientists designing and validating high-sensitivity LC-MS/MS methods and managing OOS/OOT nitrosamine investigations.
• Process Chemistry & Technical Services Departments – Engineers modifying synthetic routes, managing solvent recoveries, and scaling up API processes.
• Formulation Development Departments – Formulators modifying solid/liquid dosage forms, evaluating excipient nitrites, and designing anti-nitrosamine mitigation strategies.
• Manufacturing Operations Departments – Supervisors executing site transfers, managing cleanrooms, and overseeing facility configuration changes.
• Supplier Quality Departments – Auditors evaluating raw material vendors, KSM manufacturers, and chemical recycling sub-contractors.

Course Director: G. Sundar

G. Sundar is a quality practitioner with vast 35 years’ experience in the field of Quality Assurance, Quality Control, Bioequivalence and Pharmaceutical Regulations. His quality management experience covers the implementation of Quality tools in bulk drugs, formulation companies and CRO. He is an expert in Total Quality Systems as per GLP, GDP and as per EMEA, USFDA, MHRA and MCC, TGA, ANVISA, Japan guidelines. He has conducted more than 200 GMP/GLP audits including Q10 & Q11 implementation, 50 Formulation Contract Manufacturing Units (all types of formulations), 10 Contract Research and Analytical laboratories, 10 Clinical research CROs. He has also conducted 1000 plus trainings Asia, US, EU, Middle East and South-East Asia. Mr. Sundar Ganesan is the Director and Senior Consultant at PharmQA Compliance Services.